Bellus health stock
Is BELLUS Health Inc (Blu) stock a good investment? Bellus Health Inc shares are a bad long-term (1 year)* investment based on their real-time forecasting system. BLU's stock forecasts are updated every 5 minutes with the latest stock prices thanks to intelligent technical analysis of the market.
What is the symbol for BELLUS Health?
BELLUS Health is listed on the Toronto Stock Exchange (TSX) under the symbol BLU. How can I buy BELLUS Health shares? BLU shares and other Canadian stocks can be purchased through an online brokerage account.
What is bebellus Health Inc’s (Blu) latest clinical data?
BELLUS Health Inc (NASDAQ: BLU) has announced the first data from its Phase 2b study SOOTHE BLU5937 in chronic intractable cough. The data showed that the 50 mg and 200 mg twice daily doses of BLU5937 achieved statistical significance for the primary endpoint, with a placebo-adjusted reduction of 34% in the 24-hour cough frequency observed on Day 28.
When is BELLUS Health's next quarterly earnings announcement?
BELLUS Health plans to release its next quarterly report on Thursday, February 24, 2022. See BELLUS Health's revenue forecast. How has BELLUS Health's revenue changed in the past quarter? bellus health inc. (TSE:BLU) released its quarterly results on Wednesday, November 10.
Is BELLUS Health Inc stock a good investment?
If you are looking for stocks with good returns, Bellus Health Inc stock may not be a good investment for a high-risk year. Bellus Health Inc's current real-time share price is $20210910, but your current investment may be reduced in the future.
What is bellbellus Health Inc (Blu) stock price prediction for 2026?
The price of Bellus Health Inc is 20210424 USD. Based on the long term bullish forecast, BLU's stock price is forecast to be $20,260,422. For a 5-year investment, the return should be around +. Your current $100 investment could grow to $100 in 2026.
![:diamond_shape_with_a_dot_inside:]( ":diamond_shape_with_a_dot_inside:")
What's driving BELLUS Health's (blu-5937) stock higher Monday?
Investors excited about the company's top candidate, BLU5937, pushed shares higher at 10:30 a.m. ET on Monday. Bellus Health's lead candidate is a potential first-in-class P2X3 inhibitor for the treatment of chronic intractable cough (RCC) and pruritus associated with eczema.
Why is BELLUS Health (Blu) soaring?
Bellus Health (NASDAQ:BLU), a clinical-stage biotech company, is growing in response to positive data from clinical trials. Investors excited about the company's top candidate, BLU5937, pushed shares higher at 10:30 a.m. ET on Monday.
![:brown_circle:]( ":brown_circle:")
Will BELLUS Health (Blu) stock price drop or rise?
Yes. Bellus Health's stock price could fall dollar-for-dollar. The change is %. Will Blue's share price rise/rise/rise?
![:brown_circle:]( ":brown_circle:")
Is BELLUS Health (Blu) a biopharma research company?
(See TipRanks for OBSV stock analysis) BELLUS Health (BLU) The second stock they look at, BELLUS Health, is also a clinical-stage biopharma company, but the focus here is one that few people consider.
Who owns Blublu stock?
Several institutional investors sold shares of BLU in the past quarter, including Point72 Asset Management, Polar Capital Holdings Plc, Janus Henderson Group PLC, Laurion Capital Management LP, Morgan Stanley and Cubist Systematic Strategies LLC. Who are the main investors buying BELLUS Health shares?
What will be BELLUS Health's stock price in the next year?
On average, they expect BELLUS Health's stock price to hit $100 in the next year. This indicates a possible rise in the current share price.
![:eight_spoked_asterisk:]( ":eight_spoked_asterisk:")
What does BELLUS Health do?
Sign up to receive the latest news and reviews from BELLUS Health and its competitors in the FREE daily MarketBeats newsletter. bellus health inc. is a biopharmaceutical discovery and development company dedicated to the discovery and development of novel treatments for chronic cough and other hypersensitivity disorders.
Is there an upside for BELLUS Health (bellus)?
Based on the C$ Analyst price target, BELLUS Health predicts an increase in the current C$ rate. BELLUS Health has only been the subject of 4 research reports in the past 90 days. BELLUS Health received 126 "Outrun" votes. (Add your "Superiority" vote.)
![:brown_circle:]( ":brown_circle:")
Why is bebellus health (Blu) stock rocketing higher on Monday?
Shares of BELLUS Health (NASDAQ:BLU) rose on Monday, boosted by data from a phase 2b clinical trial. Source: Shutterstock This clinical trial tested the efficacy of BLU5937 in the treatment of chronic intractable cough.
Is there an upside in BELLUS Health's price?
Based on the C$ Analyst price target, BELLUS Health predicts an increase in the current C$ rate. BELLUS Health has only been the subject of 4 research reports in the past 90 days. BELLUS Health received 126 "Outrun" votes.
Who is bebellus health?
BELLUS Health is a clinical stage pharmaceutical company developing a P2X3 antagonist for the treatment of various hypersensitivity afferent diseases. The company's lead candidate, BLU5937, is currently in Phase 2 clinical trials for chronic intractable cough and chronic pruritus associated with atopic dermatitis.
![:diamond_shape_with_a_dot_inside:]( ":diamond_shape_with_a_dot_inside:")
Where can I find more information about BELLUS Health?
They invite you to visit their Investor Relations page, including their annual information form, to learn more about BELLUS Health.
![:brown_circle:]( ":brown_circle:")
Is BELLUS Health’s blu-5937 effective for chronic cough?
Bellus Health (BLU) met the primary endpoint of a phase IIb study evaluating BLU5937 for the treatment of intractable chronic cough.
![:diamond_shape_with_a_dot_inside:]( ":diamond_shape_with_a_dot_inside:")
What is bebellus' blu-5937?
BELLUS' lead candidate, BLU5937, is being evaluated for its efficacy in treating these symptoms. BLU5937 is a highly selective PsX3 antagonist that acts on the P2X3 receptor in the cough reflex pathway. The current clinical trial is a phase 2b follow-up to the phase 2 RELIEF trial.
What is be bellus health inc's (blu) latest clinical data report
bellus health inc. announced the completion of patient enrollment in the BLU5937 Phase 2b SOOTHE Clinical Trial for Chronic Refractory Cough ("RCC") and the Phase 2a BLUEPRINT Clinical Trial for BLU5937 Chronic Pruritus Associated with Atopic Dermatitis ("AD"). ). ). The first results of the two studies are expected in December 2021.
What is BELLUS Health’s lead drug candidate blu-5937?
The company's lead candidate, BLU5937, is currently in Phase 2 clinical trials for chronic intractable cough and chronic pruritus associated with atopic dermatitis. They invite you to visit their Investor Relations page, including their annual information form, to learn more about BELLUS Health.
![:diamond_shape_with_a_dot_inside:]( ":diamond_shape_with_a_dot_inside:")
Is bluestone Inc (Blu) stock a good buy?
With 3 buys and no offers or sales, Street says BLU is a strong buy. In dollars, the average price target suggests upside potential of about 134%.
![:diamond_shape_with_a_dot_inside:]( ":diamond_shape_with_a_dot_inside:")
What is BELLUS Health doing to treat afferent hypersensitization?
BELLUS investigates how activation of P2X3 contributes to irritation and pain, and whether inhibition of P2X3 receptors could aid in the treatment of other afferent hypersensitivity disorders. invite you to visit their investor relations page, including their annual information form, to learn more about BELLUS Health.
What is BELLUS Health's blu-5937?
Bellus Health is currently developing BLU5937 for the treatment of chronic cough and chronic itching. These diseases represent areas of high unmet medical need and significant commercial opportunity. BLU5937 is still under development and has not been approved for commercial use.
![:brown_circle:]( ":brown_circle:")
What does BELLUS Health stand for?
LAVAL, Quebec (BUSINESS WIRE) BELLUS Health Inc. (Nasdaq:BLU TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing new treatments for these pennystocks, could be the target when they turn the page in the new month .
Why is bebellus health (Blu) stock trading higher Monday?
Shares of BELLUS Health Inc (NASDAQ:BLU) traded higher Monday after the company announced an interim analysis of its phase 2b study SOOTHE BLU5937 for the treatment of chronic intractable cough.
![:eight_spoked_asterisk:]( ":eight_spoked_asterisk:")
What is be bellus health inc's (blu) latest clinical data review
BLU5937 is a P2X3 antagonist with high selectivity (more than 1500 fold) for the cognate P2X2/3 receptor. In healthy volunteers, BLU5937 showed good pharmaceutical and pharmacokinetic properties. 1 Bellus Health is currently developing BLU5937 for the treatment of chronic cough and chronic itching.
![:brown_circle:]( ":brown_circle:")
What is be bellus health inc's (blu) latest clinical data information
BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops therapeutic products for the treatment of chronic cough and other hypersensitivity disorders. The lead drug candidate is BLU5937, a small molecule ■■■■ P2X3 receptor antagonist in Phase II clinical trials for the treatment of chronic cough and chronic pruritus.
What is bebellus health?
BELLUS Health (Nasdaq: BLU, TSX: BLU) is a clinical-stage biotechnology company developing new treatments for chronic cough and other conditions caused by chronic hypersensitivity.
Who bought Blu stock in the last quarter?
BLU shares were bought in the quarter by a number of institutional investors, including Asymmetry Capital Management, Sectoral Asset Management Inc, Tri Locum Partners LP, Artal Group, Ensign Peak Advisors Inc, Affinity Asset Advisors LLC, Schonfeld Strategic Advisors LLC and Jefferies.. LLC group.
![:diamond_shape_with_a_dot_inside:]( ":diamond_shape_with_a_dot_inside:")
How did bebellus health (Blu) perform in Q4 earnings?
bellus health inc. (TSE:BLU) released its quarterly results on Wednesday, November 10. The company reported earnings per share ($) for the quarter, lower than analysts' consensus estimate of ($)$. The company made millions of dollars in the quarter, compared to analyst estimates of millions of dollars.
![:eight_spoked_asterisk:]( ":eight_spoked_asterisk:")
What is the upside for BELLUS Health's stock price?
On average, they expect BELLUS Health's stock price to hit the Canadian dollar in the coming year. This indicates a possible rise in the current share price. View BELLUS Health Analysts price targets or explore Wall Street Analysts' top rated stocks.
![:brown_circle:]( ":brown_circle:")
What are analysts'target prices for BELLUS Health's stock?
5 Equity Research analysts have released 12-month target prices for BELLUS Health stocks. His forecast varies between Canadian dollars and Canadian dollars. On average, they expect BELLUS Health's stock price to hit the Canadian dollar next year. This indicates a possible rise in the current share price.
What is BELLUS Health's price targets for the next year?
5 brokerage houses have published target prices for 1-year BELLUS Health shares. Your forecast varies between $ and $. On average, they expect BELLUS Health's stock price to hit $100 in the next year. This indicates a possible rise in the current share price.
Is there an upside in BELLUS Health stock?
Based on analysts' consensus price in $, BELLUS Health predicts an increase from the current price in $. BELLUS Health has only been the subject of 4 research reports in the past 90 days. BELLUS Health received 18 "Exceeded" votes.
Who owns bebellus health's stock?
BELLUS Health stocks are owned by a number of retail and institutional investors. The main institutional investors are Artal Group , Polar Capital Holdings Plc , Laurion Capital Management LP , Sectoral Asset Management Inc , Janus Henderson Group PLC and Asymmetry Capital Management .
![:diamond_shape_with_a_dot_inside:]( ":diamond_shape_with_a_dot_inside:")
Who is BELLUS Health?
Company Profile BELLUS Health is a clinical-stage biotechnology company developing novel therapies for chronic cough and other hypersensitivity disorders. NASDAQTSX
What is the weather like in Whistler?
WEATHER: AVERAGE MONTHLY WEATHER in Whistler, Canada. The climate in Whistler is cold and temperate. There is usually more rainfall in winter than in summer. The average annual temperature is about 6 degrees Celsius (43 degrees Fahrenheit).
![:eight_spoked_asterisk:]( ":eight_spoked_asterisk:")
What is Whistler like in the summer?
Whistler is beautiful in the summer, especially if the weather permits. As other posters have mentioned, it is definitely a busy place in the summer, especially on weekends and holidays. But the scenery is breathtaking and there is something for all ages to do.
![:eight_spoked_asterisk:]( ":eight_spoked_asterisk:")
What to eat in Whistler?
What to eat in Whistler. The menu includes delicacies such as goat cheese ravioli, grilled Vancouver Island octopus, Arctic char, Qualicum scallops, Alberta strip steak, melted chocolate cake, petit four, and more. There is also a raw food bar, a tasting menu and a fantastic selection of cheeses.
![:brown_circle:]( ":brown_circle:")
How far is Whistler from Bellingham?
Map of the best route between Bellingham, Washington and Whistler, British Columbia, Canada. The length of this route will be approximately 130 kilometers.
